Biogen (BIIB) PT Raised to $225 at Cowen

April 22, 2021 4:22 PM EDT
Get Alerts BIIB Hot Sheet
Price: $280.21 -0.53%

Rating Summary:
    16 Buy, 19 Hold, 5 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 30 | Down: 4 | New: 24
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Cowen analyst Phil Nadeau raised the price target on Biogen (NASDAQ: BIIB) to $225.00 (from $215.00) while maintaining a Market Perform rating.

The analyst commented, "BIIB reported Q1 revenue in line with and Q1 EPS just above consensus on expense control. 2021 revenue guidance was reiterated. Major Q2 events will determine if BIIB's revenue grows or declines in future years: Adu's 6/7 PDUFA, zuranolone's WATERFALL data, and a decision in the Tecfidera appeal. Our DCF-based price target is increased from $215 to $225, and we maintain at Market Perform."

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Cowen & Co, PDUFA